# Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg

> **NCT05160090** · PHASE1 · COMPLETED · sponsor: **Alembic Pharmaceuticals Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Bupropion HCl MR tablets 300mg

## Key facts

- **NCT ID:** NCT05160090
- **Lead sponsor:** Alembic Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-18
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-02-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160090, "Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05160090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*